Latest News

Genetic evidence that new therapies targeting Parkinson's disease may cause harm

Researchers have completed a small study that shows genetic and clinical evidence that therapies targeting the expression of alpha-synuclein -- a gene whose function is involved in the development and progression of Parkinson?s disease -- may accelerate disease progression and increase the risk of physical incapacitation and dementia. If replicated, the findings will have profound implications for therapies under development for Parkinson?s disease.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Use it or lose it: Active learning improves cognitive learning in active adults

  • Good bedtime habits equal better sleep for kids

  • Ads effective even in the midst of multitasking, studies find

  • Chronic insomniacs may face increased risk of hypertension

  • Largest-ever autism genome study finds most siblings have different autism-risk genes

  • Possible therapeutic target for common, but mysterious brain blood vessel disorder

  • Higher dementia risk linked to more use of common drugs

  • Girls lead boys in academic achievement globally

  • Students master math through movement using Kinect for Windows

  • Phase 1 clinical trial of CUDC-101 'throws kitchen sink' at head and neck cancer

  •